Phenylacetic Acid

Phenylacetic Acid

SCHEMBL6188575

O=C(O)Cc1ccccc1.O=C1NC(=O)C(Cc2cccc(-c3ccccc3)c2)S1

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 6/20 0.65
PPARG P37231 3/20 0.52
ALDH1A1 P00352 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
MAOB P27338 2/20 0.47
MAOA P21397 2/20 0.47
CISD1 Q9NZ45 2/20 0.47
MAPT P10636 2/20 0.47
CA2 P00918 1/20 0.47
PPARA Q07869 1/20 0.46
FLT3 P36888 1/20 0.46
LMNA P02545 2/20 0.45
ABCC4 O15439 1/20 0.45
GAA P10253 1/20 0.45
TSHR P16473 1/20 0.45
PTGS1 P23219 1/20 0.45
HTT P42858 1/20 0.45
GRIN2D O15399 1/20 0.45
GRIN3B O60391 1/20 0.45
GRIN1 Q05586 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6202350 0.92 FFAR1 (0.73) FFAR1PPARGALDH1A1NPSR1MAOB
SCHEMBL6185074 0.84 FFAR1 (0.61) FFAR1PPARGALDH1A1NPSR1MAOB
SCHEMBL6187592 0.82 FFAR1 (0.53) FFAR1PPARG
SCHEMBL6183905 0.81 FFAR1 (0.59) FFAR1PPARG
SCHEMBL6184667 0.80 FFAR1 (0.59) FFAR1PPARGALDH1A1NPSR1MAPT
SCHEMBL166570 0.79 PPARG (0.74) FFAR1PPARGALDH1A1NPSR1MAOB
SCHEMBL5395861 0.79 FFAR1 (0.63) FFAR1PPARGALDH1A1NPSR1MAOB
SCHEMBL1746645 0.79 FFAR1 (1.00) FFAR1PPARGPPARA
SCHEMBL6184912 0.78 FFAR1 (0.59) FFAR1PPARGALDH1A1NPSR1MAOB
SCHEMBL6184691 0.78 FFAR1 (0.54) FFAR1PPARGALDH1A1NPSR1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6927228-B2 Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-09 US claimed
EP-1309575-B1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RES & DEV (FR) 2005-06-08 EP claimed
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-26 US claimed
US-6927228-B2 Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-09 US disclosed
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors PPARG, PPARA, PPARD FFAR1 6/4885PPARG 1/4885ALDH1A1 378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.